سعر بريستمود 50مجم ممتد المفعول 20 قرص 2026

Desvenlafaxine 50 mg extended-release tablets, pack of 20 (Medizen Pharmaceutical Industries, Egypt).

• Treatment of adults with major depressive disorder (MDD).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Hypersensitivity to desvenlafaxine succinate, venlafaxine or excipients; use of MAOIs for psychiatric disorders with or within 7 days of stopping desvenlafaxine, or starting it within 14 days of stopping an MAOI; starting in patients on linezolid or IV methylene blue.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: antidepressants increased the risk of suicidal thoughts and behaviours in children, adolescents and young adults; monitor all patients closely for clinical worsening and suicidality.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serotonin syndrome, elevated blood pressure, increased bleeding risk, angle-closure glaucoma, activation of mania/hypomania, discontinuation syndrome, seizures, hyponatraemia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• MAO inhibitors (incl. linezolid, IV methylene blue)Contraindicated combination: risk of serotonin syndrome.DailyMed (U.S. National Library of Medicine)
• NSAIDs, aspirin, warfarin and other drugs affecting haemostasisIncreased risk of bleeding.DailyMed (U.S. National Library of Medicine)

• Observational data: SNRI exposure, particularly in the month before delivery, associated with a less than 2-fold increased risk of postpartum haemorrhage; pregnancy exposure registry available.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Limited published data show low levels of desvenlafaxine in human milk without adverse reactions in breastfed infants; no data on milk production.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Desvenlafaxine: Thought to potentiate serotonin and norepinephrine in the CNS through inhibition of their reuptake; potent and selective SNRI lacking significant muscarinic, H1 or alpha1 affinity and MAO-inhibitory activity (US PRISTIQ label 12.1-12.2).